SCHEMBL858580

SCHEMBL858580

Cc1nc(Cl)c(C)c(Nc2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.50
KDR P35968 2/20 0.50
KMT2A Q03164 6/20 0.48
MEN1 O00255 4/20 0.48
RXFP1 Q9HBX9 1/20 0.48
NPY5R Q15761 1/20 0.47
MAPK1 P28482 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 2/20 0.44
NFKB1 P19838 1/20 0.44
BCL6 P41182 1/20 0.44
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 2/20 0.43
TP53 P04637 1/20 0.42
JAK2 O60674 1/20 0.41
LRRK2 Q5S007 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13157161 0.78 KMT2A (0.50) EGFRKDRKMT2AMEN1NPY5R
SCHEMBL13351818 0.77 KMT2A (0.51) EGFRKDRKMT2AMEN1RXFP1
SCHEMBL855999 0.76 EGFR (0.54) EGFRKDRMAPK1CYP3A4MAPT
SCHEMBL20873888 0.76 KMT2A (0.44) EGFRKDRKMT2AMEN1RXFP1
SCHEMBL8801133 0.75 PDE4B (0.45) EGFRKDRKMT2AMEN1RXFP1
SCHEMBL13861627 0.75 NPY5R (0.61) KDRKMT2AMEN1NPY5RMAPK1
SCHEMBL3974545 0.74 NPY5R (0.66) EGFRKDRKMT2AMEN1NPY5R
SCHEMBL31086656 0.73 KMT2A (0.47) EGFRKDRKMT2AMEN1NPY5R
SCHEMBL11001309 0.71 EGFR (0.48) EGFRKDRKMT2AMEN1RXFP1
SCHEMBL5843261 0.71 RAPGEF4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA EGFR 1918/4885KDR 2561/4885KMT2A 2645/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA EGFR 1831/4885KDR 2886/4885KMT2A 3064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.